Cat. No. / Size
Price
Availability
Qty
CLD-H5253-100ug
$380.00
CLD-H5253-1mg (500ug × 2)
$2,860.00
CLD-H5253
Sub-Total :
$ 0
0
Add to Cart
Customize Product Request Quote
Contact Us
Contact Us
Sub-Total:
$ 0
0
Add to Cart
  • Performance Data
  • Reviews & Citations
  • Important Statement
  • Resources

分子别名(Synonym)

CLEC2D, C-type lectin domain family 2 member D, Lectin-like NK cell receptor, Lectin-like transcript 1, LLT-1, Osteoclast inhibitory lectin

表达区间及表达系统(Source)

Human CLEC2D, Mouse IgG2a Fc Tag (CLD-H5253) is expressed from human 293 cells (HEK293). It contains AA Arg 60 - Val 191 (Accession # Q9UHP7-1).

Predicted N-terminus: Glu

Request for sequence

蛋白结构(Molecular Characterization)

CLEC2D Structure

This protein carries a mouse IgG2a Fc tag at the N-terminus

The protein has a calculated MW of 42.2 kDa. The protein migrates as 45-55 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

内毒素(Endotoxin)

Less than 0.1 EU per μg by the LAL method.

纯度(Purity)

>95% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 25 mM Arginine, 150 mM NaCl, pH7.5 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.

Background

CLEC2D (C-type lectin domain family 2 member D) is also known as CLAX, LLT1, OCIL is receptor for KLRB1 that protects target cells against natural killer cell-mediated lysis, inhibits osteoclast formation, inhibits bone resorption and modulates the release of interferon-gamma. It is also a ligand for the human NKR-P1A (CD161) receptor, present on NK cells and T cells. Furthermore, The reference shows the pathway may as a potential immunotherapy targets.